Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis

Pediatric Pulmonology

Volumn 41, Issue 7, 2006, Pages 656-665

  Gibson, Ronald L ^a,j   Retsch Bogart, George Z ^b   Oermann, Christopher ^c   Milla, Carlos ^d   Pilewski, Joseph ^e   Daines, Cori ^f   Ahrens, Richard ^g   Leon, Kevin ^h   Cohen, Morty ^a   McNamara, Sharon ^a   Callahan, Tracy L ^b   Markus, Richard ⁱ   Burns, Jane L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^f CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^g UNIVERSITY OF IOWA   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁱ Corus Pharma Inc ^*  (United States)

^j SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

more..

Author keywords

Aztreonam lysinate; Cystic fibrosis; Inhaled antibiotics; Pseudomonas aeruginosa

Indexed keywords

AZTREONAM; AZTREONAM LYSINATE; PLACEBO; TOBRAMYCIN; UNCLASSIFIED DRUG;

ADOLESCENT; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FORCED EXPIRATORY VOLUME; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; NEBULIZER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPUTUM ANALYSIS;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AZTREONAM; CYSTIC FIBROSIS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; SPUTUM;

EID: 33745686502     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.20429     Document Type: Article

References (27)

1. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003;168:918-951.
2. Doring G, Conway SP, Heijerman HG, Hodson M, Hoiby N, Smyth AR, Touw DJ. Antibitotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000;16:749-767.
3. Kerem E, Corey M, Gold R, Levison H. Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J Pediatr 1990; 116:714-719.
4. Pamukcu A, Bush A, Buchdahl R. Effects of Pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis. Pediatr Pulmonol 1995; 19:10-15.
5. Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 1992;12:158-161.
6. Tan KH, Mulheran M, Knox AJ, Smyth AR. Aminoglycoside prescribing and surveillance in cystic fibrosis. Am J Respir Crit Care Med 2003;167:819-823.
7. Burns JL, Emerson J, Stapp JR, Yim DL, Krzewinski J, Louden L, Ramsey BW, Clausen CR. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis 1998;27:158-163.
8. Mendelman PM, Smith AL, Levy J, Weber A, Ramsey B, Davis RL. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am Rev Respir Dis 1985;132:761-765.
9. Beggs WH, Andrews FA. Role of ionic strength in salt antagonism of aminoglycoside action on Escherichia coli and Pseudomonas aeruginosa. J Infect Dis 1976;134:500-504.
10. Bodem CR, Lampton LM, Miller DP, Tarka EF, Everett ED. Endobronchial pH. Relevance of aminoglycoside activity in gram-negative bacillary pneumonia. Am Rev Respir Dis 1983;127:39-41.
11. Ramphal R, Lhermitte M, Filliat M, Roussel P. The binding of anti-pseudomonal antibiotics to macromolecules from cystic fibrosis sputum. J Antimicrob Chemother 1988;22:483-490.
12. Potter JL, Matthews LW, Spector S, Lemm J. Complex formation between basic antibiotics and deoxyribonucleic acid in human pulmonary secretions. Pediatrics 1965;36:714-720.
13. Vaudaux P, Waldvogel FA. Gentamicin inactivation in purulent exudates: role of cell lysis. J Infect Dis 1980;142:586-593.
14. Brewer NS, Hellinger WC. The monobactams. Mayo Clin Proc 1991;66:1152-1157.
15. Azactam™ (aztreonam for injection USP). Fact sheet update. Princeton, NJ: Bristol-Meyers Squibb Company; 2004.
16. Dietzsch HJ, Gottschalk B, Heyne K, Leupoid W, Wunderlich P. Cystic fibrosis: comparison of two mucolytic drugs for inhalation treatment (acetylcysteine and arginine hydrochloride). Pediatrics 1975;55:96-100.
17. Sapienza MA, Kharitonov SA, Horvath I, Chung KF, Barnes PJ. Effect of inhaled L-arginine on exhaled nitric oxide in normal and asthmatic subjects. Thorax 1998;53:172-175.
18. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard M7-85, 5th edition. Wayne, PA: National Committee for Clinical Laboratory Standards; 2000.
19. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev K-M, Borowitz D, Bowman CM, Marshall BC, Marshall S, Smith AL. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999; 340:23-30.
20. Burns JL, Van Dalfsen JM, Shawar RM, Otto KL, Garber RL, Quan JM, Montgomery AB, Albers GM, Ramsey BW, Smith AL. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 1999;179:1190-1196.
21. Kuhn RJ. Formulation of aerosolized therapeutics. Chest 2001; 120:94s-98s.
22. Shawar RM, MacLeod DL, Garber RL, Burns JL, Stapp JR, Clausen CR, Tanaka SK. Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 1999;43:2877-2880.
23. AZACTAM® (aztreonam for injections, USP). [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2001.
24. Hofmann T, Otto K, Kirihara J, Flitter W, Mair SJ, Lintz FC, Schuschnig U, Keller M, Seemann S. Safety and tolerability study of aztreonam for inhalation (AI) in healthy volunteers [abstract 195]. Pediatr Pulmonol 2003; Suppl 25:251.
25. Caron HJ, Millard SP, Goss CH, Ramsey BW. Respiratory adverse event profiles in placebo subjects in short- and long-term inhaled therapy trials [abstract 432]. Pediatr Pulmonol 2003; Suppl 25:334.
26. Keller M, Stempfle P, Reul K, Waldner R, Opolski FC, Menges G, Seemann S, Stapleton KW. High efficiency pulmonary drug delivery of a novel formulation of aztreonam by the eFlow®. 14th Congress of ISAM, Baltimore, MD, June 14-18, 2003.
27. Keller M, Schuschnig U, Balcke A, Waldner R, Knoch M. Salbutamol nebulisation performance of eFlow IMP versus air-jet nebulisers. PARI Aerosol Research Institute, Drug Delivery to the Lungs XIII 2002; London.